Major Depressive Disorder

Vice Chair of the Performance Measurement Committee Rebecca A. Andrews spoke to HCPLive about the challenges with performance measures for treating major depressive disorder.

In an interview with HCPLive, Rebecca Andrews, MD, provided insight into the way the American College of Physicians voted on the performance measures for MDD.

Lindsey Venesky, PhD, discussed how a mental fitness vocal biomarker tool could identify mental health symptoms people might not even be aware of through their voice.

A new study found women (1.64) had a greater hazard ratio of depression for CVD than men (1.39).

This psychiatry month in review spotlights new research on detecting and treating major depressive disorder with AI, FDA’s Complete Response Letter for roluperidone, and more.

A new study found menopausal hormone therapy was associated with a significant reduction in depressive symptoms over time with a greater reduction combined with antidepressants.

MoodCapture, an app with AI that can detect depression onset from facial cues, accurately diagnosed 75% of participants in a study with early symptoms of depression.

A new study found female teens and young adults were more likely to have an increased antidepressant dispensing rate during the pandemic than male peers.

A new study found crisis response planning for PTSD among military veterans had lower onset of suicidal ideation than veterans with self-guided safety planning.

A new study found engaging the amygdala can help with memory recall for individuals with depression—and familiar scents helped more than word cues. Memories with odor cues were more arousing and vivid.

A secondary analysis found a brain scan with an AI algorithm predicted within a week 1/3 of patients would respond to sertraline and 2/3 would not.

Telehealth appointments, patients who prefer speaking non-English, older adults, and patients on Medicaid had lower odds of having a depression screening during the early COVID-19 pandemic.

A study found adolescents with PCOS have a 5.38-fold increased risk for a suicide attempt, and adults have an 8.75-fold increased risk.

A pooled analysis showed patients on cariprazine for major depressive disorder had only mild to moderate treatment-emergent adverse events.

Although a new study found antidepressants from SSRI or SNRI did not increase the risk of hemorrhagic stroke or other serious bleeding in ischemic stroke survivors, the risk increased when taking antidepressants of other classes and anti-platelet medications.

Our January 2024 psychiatry month in review includes studies finding associations with depression, anxiety, and anorexia nervosa, as well as a phase 3 study looking into long-term safety of olanzapine, samidorphan.

A new survey study of high schoolers found alcohol, cannabis, and nicotine were linked to significant, moderate dose-dependent associations with worse symptoms of depression, anxiety, ADHD, general mental health, as well as suicidal thoughts.

Dr Andrew Cutler and Dr Greg Mattingly comment about emerging treatments to treat anhedonia and highlight lifestyle modifications that support the wellbeing of patients with Major Depressive Disorder.

A new study found behavioral activation therapy is just as effective as antidepressants for treating depressive symptoms in patients with heart failure, with both treatments having a 50% reduction at months 3, 6, and 12.

Respondents in trigger states had significantly greater increased anxiety and depression symptoms following the Dobbs abortion decision on June 24, 2022 than respondents in non-trigger states.

Analysis finds measures of iron deficiency, including ferritin, serum iron, and transferrin, were linked to an increased likelihood of depression in young adult males but not females.

For every increment increase in a participant’s usual score for depressive symptoms, investigators of a new study found weight increased a month later by 45g, only for participants with overweight and obesity.

A new study found, after bariatric surgery, participants had a 9.5% reduction in anxiety and a 22.3% reduction in depression.

A new study does not support the home-use tDCS since the findings show the home-use tDCS combined with either a digital psychological intervention or digital placebo was not superior to the sham.